8-K: Xilio Therapeutics Announces Promising Initial Data for Vilastobart Combination Therapy and Third Quarter Financial Results

Xilio Therapeutics reported encouraging initial Phase 1C clinical trial data for vilastobart in combination with atezolizumab, along with third quarter 2024 financial results and pipeline updates.

Summary

• Xilio Therapeutics announced its third quarter 2024 financial results and provided updates on its clinical pipeline.
• The company presented initial Phase 1C data for vilastobart (XTX101) in combination with atezolizumab, showing encouraging anti-tumor activity in patients with advanced solid tumors.
• Two unconfirmed partial responses were observed, including a complete resolution of a metastatic liver lesion in a patient with microsatellite stable colorectal cancer (MSS CRC).
• The combination therapy was generally well-tolerated, with minimal immune-related adverse events.
• Xilio expects to report initial Phase 2 data for vilastobart in combination with atezolizumab in approximately 20 patients with MSS CRC in the fourth quarter of 2024.
• Additional Phase 2 data for approximately 40 patients with MSS CRC is expected in the first quarter of 2025.
• The company's cash and cash equivalents were $61.3 million as of September 30, 2024, compared to $44.7 million as of December 31, 2023.
• License revenue for the quarter ended September 30, 2024, was $2.3 million, primarily from the Gilead agreement.
• Research and development expenses were $10.8 million for the quarter ended September 30, 2024, compared to $11.1 million for the same period in 2023.
• Net loss for the quarter ended September 30, 2024, was $14.0 million, compared to $16.7 million for the same period in 2023.
• Xilio anticipates its current cash will fund operations through the end of the second quarter of 2025.
• The company is also advancing XTX301, a tumor-activated IL-12, and expects to report Phase 1 data in the fourth quarter of 2024.

Sentiment

Score: 8

Explanation: The document presents positive clinical data and financial updates, suggesting a strong outlook for the company. The initial results are promising, and the company has a clear path forward with multiple upcoming milestones. However, the need for future funding and the inherent risks of drug development temper the overall sentiment.

Positives

• The Phase 1C trial of vilastobart and atezolizumab showed promising early anti-tumor activity, including partial responses in patients with difficult-to-treat cancers.
• The combination therapy demonstrated a favorable safety profile with minimal immune-related adverse events.
• The company has a strong cash position of $61.3 million, providing a runway through the second quarter of 2025.
• Xilio has a co-funded clinical trial collaboration with Roche for vilastobart and an exclusive license agreement with Gilead for XTX301.
• The company is advancing multiple research-stage programs, including tumor-activated bispecific and immune cell engager molecules.

Negatives

• The company reported a net loss of $14.0 million for the third quarter of 2024.
• Research and development expenses remain high at $10.8 million for the quarter.
• The partial responses observed in the Phase 1C trial are unconfirmed and require further validation.
• The company's cash runway is only projected to last through the second quarter of 2025, indicating a potential need for future capital raises.

Risks

• The clinical trial results are preliminary and may not be replicated in larger studies.
• The company's product candidates may not receive regulatory approval.
• Xilio may face challenges in obtaining and maintaining sufficient cash resources to fund its operations.
• The company's collaborations with Roche and Gilead could be impacted by various factors.
• There are risks associated with the development of novel therapies, including potential safety issues and efficacy concerns.

Future Outlook

Xilio anticipates reporting initial Phase 2 data for vilastobart in combination with atezolizumab in MSS CRC in the fourth quarter of 2024 and additional data in the first quarter of 2025. The company also expects to report Phase 1 data for XTX301 in the fourth quarter of 2024. Xilio's current cash is expected to fund operations through the end of the second quarter of 2025.

Management Comments

• Ren Russo, Pharm.D., president and chief executive officer of Xilio, stated that the team continued to drive execution across all stages of the pipeline.
• Ren Russo also expressed encouragement by the potentially differentiated safety profile and two unconfirmed partial responses observed in the Phase 1C trial.
• Diwakar Davar, M.D., lead author of the study, noted the lack of effective treatment options for MSS colorectal cancer and the encouraging early data for vilastobart.

Industry Context

The announcement is significant in the context of the immuno-oncology field, particularly for the treatment of MSS colorectal cancer, which has historically been resistant to immunotherapy. The positive initial data for vilastobart in combination with atezolizumab could represent a potential breakthrough in this area. The company's focus on tumor-activated therapies aligns with the industry's trend towards developing more targeted and less toxic treatments.

Comparison to Industry Standards

• The reported partial response rate in the Phase 1C trial, while unconfirmed, is notable compared to the low response rates typically seen with checkpoint inhibitors in MSS CRC, which are often in the 0-3% range.
• The safety profile of the vilastobart and atezolizumab combination appears favorable compared to other anti-CTLA-4 therapies, which are often associated with significant immune-related adverse events.
• The company's approach of using tumor-activated molecules is a differentiating factor compared to traditional systemic immunotherapies, which can lead to off-target toxicities.
• Competitors in the anti-CTLA-4 space include companies like Bristol Myers Squibb with ipilimumab, but Xilio's tumor-activated approach aims to improve the therapeutic index.
• The development of tumor-activated IL-12 (XTX301) is also significant, as systemic IL-12 has historically been limited by toxicity, and Xilio's approach aims to overcome this limitation.

Stakeholder Impact

• Shareholders may react positively to the encouraging clinical data and financial updates.
• Employees may be motivated by the progress of the company's pipeline.
• Patients with advanced solid tumors, particularly MSS CRC, may benefit from the development of new treatment options.
• The company's collaborations with Roche and Gilead could lead to further advancements in cancer therapy.

Next Steps

• Xilio will continue to enroll patients in the Phase 2 clinical trial for vilastobart in combination with atezolizumab in MSS CRC.
• The company plans to report initial Phase 2 data for the combination in approximately 20 patients with MSS CRC in the fourth quarter of 2024.
• Additional Phase 2 data for approximately 40 patients with MSS CRC is expected in the first quarter of 2025.
• Xilio will report Phase 1 data for XTX301 in the fourth quarter of 2024.
• The company will continue to advance its research-stage programs, including XTX501 and tumor-activated cell engagers.

Key Dates

Keywords

immuno-oncology, vilastobart, XTX101, atezolizumab, colorectal cancer, MSS CRC, tumor-activated, anti-CTLA-4, IL-12, XTX301, clinical trial, biotechnology, cancer therapy, immunotherapy